Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PTPRB | P23467 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17617193 | 0.88 | ALDH1A1 (0.33) | ALDH1A1TSHRPOLBPKM | |
| SCHEMBL17617155 | 0.88 | ALDH1A1 (0.33) | ALDH1A1TSHRPOLBPKM | |
| SCHEMBL809243 | 0.85 | DGAT1 (0.40) | ALDH1A1TSHRHSD17B10TDP1DGAT1 | |
| SCHEMBL29674742 | 0.83 | DGAT1 (0.39) | ALDH1A1TSHRHSD17B10DGAT1MGAM | |
| SCHEMBL17617138 | 0.83 | ALDH1A1 (0.46) | ALDH1A1TSHRHSD17B10LMNAMGAM | |
| SCHEMBL423150 | 0.82 | ALDH1A1 (0.39) | ALDH1A1TSHRHSD17B10TDP1LMNA | |
| SCHEMBL17617154 | 0.79 | TSHR (0.43) | ALDH1A1TSHRLMNA | |
| SCHEMBL17617189 | 0.78 | ALDH1A1 (0.36) | ALDH1A1TSHRHSD17B10TDP1LMNA | |
| SCHEMBL17617140 | 0.78 | ALDH1A1 (0.36) | ALDH1A1TSHRHSD17B10TDP1LMNA | |
| SCHEMBL4901424 | 0.78 | ALDH1A1 (0.38) | ALDH1A1TSHRHSD17B10TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083341-A1 | METHOD FOR PRODUCING a-SUBSTITUTED CYSTEINE OR SALT THEREOF OR SYNTHETIC INTERMEDIATE OF a-SUBSTITUTED CYSTEINE | API CORPORATION (JP) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083341-A1 | METHOD FOR PRODUCING a-SUBSTITUTED CYSTEINE OR SALT THEREOF OR SYNTHETIC INTERMEDIATE OF a-SUBSTITUTED CYSTEINE | MGMT, GSTA1, CBS | ALDH1A1 236/4885TSHR 1898/4885HSD17B10 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.